Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: Study of miconazole lauriad® efficacy and safety (SMiLES)

HIV Clinical Trials

Volumn 11, Issue 4, 2010, Pages 186-196

  Vazquez, José ^a,b   Patton, Lauren ^c   Epstein, Joel ^d   Ramlachan, Padaruth ^e   Mitha, Ismail ^f   Noveljic, Zoja ^g   Fourie, Jan ^h   Conway, Brian ⁱ   Lalla, Rajesh ^j   Barasch, Andrei ^k   Attali, Pierre ^l,m  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Durban Electricity Department   (South Africa)

^f Benmed Park Clinic   (South Africa)

^g Karl Bremer Hospital   (South Africa)

^h University of British Columbia ^*

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l BioAlliance Pharma   (France)

^m BICÊTRE HOSPITAL   (France)

more..

Author keywords

antifungal agents; clotrimazole; HIV related opportunistic infections; miconazole; oral candidiasis

Indexed keywords

CLOTRIMAZOLE; LAURIAD; MICONAZOLE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OROPHARYNX CANDIDIASIS; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; TROCHE; XEROSTOMIA;

EID: 78049426668     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1104-186     Document Type: Article

References (40)

1. Botter AA. Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen. 1971;14(4):187-191.
2. Quatresooz P, Vroome V, Borgers M, et al. Novelties in the multifaceted miconazole effects on skin disorders. Expert Opin Pharmacother. 2008;9(11):1927-1934.
3. Fothergill AW. Miconazole: a historical perspective. Expert Rev Anti Infect Ther. 2006;4(2):171-175.
4. Francois IEJA, Cammune BPA, Borgers M, et al. Azoles: mode of antifungal action and resistance development. effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-Infect Agents Medicinal Chem. 2006;5:3-13.
5. Shin ES, Chung SC, Kim YK, et al. The relationship between oral Candida carriage and the secretor status of blood group antigens in saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(1):48-53.
6. Epstein JB. Diagnosis and treatment of oropharyn-geal candidiasis. Oral Maxillofac Surg Clin North Am. 2003;15(1):91-102.
7. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am. 2002;16(4):793-820, v.
8. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS. 2000;14(8):979-985.
9. Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defi c Syndr. 1999;21(1):20-25.
10. Greenspan D, Canchola AJ, MacPhail LA, et al. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet. 2001;357(9266):1411- 1412.
11. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
12. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207; quiz CE201-204.
13. Albengres E, Le Louet H, Tillement J P. Systemic antifungal agents. Drug interactions of clinical signifi cance. Drug Saf. 1998;18(2):83-97.
14. Baccaglini L, Atkinson JC, Patton LL, et al. Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 (Suppl:S50):e51-23.
15. Cardot JM, Chaumont C, Dubray C, et al. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharmacol. 2004;58(4):345-351.
16. Murray PA, Koletar SL, Mallegol I, et al. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther. 1997;19(3):471-480.
17. Loe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand. 1963;21:533-551.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
19. Koletar SL, Russell JA, Fass RJ, et al. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodefi ciency virus. Antimicrob Agents Chemother. 1990;34(11):2267-2268.
20. Linpiyawan R, Jittreprasert K, Sivayathorn A. Clinical trial: clotrimazole troche vs. itraconazole oral solution in the treatment of oral candidosis in AIDS patients. Int J Dermatol. 2000;39(11):859-861.
21. Pons V, Greenspan D, Debruin M. Therapy for oropha-ryngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defi c Syndr. 1993;6(12):1311-1316.
22. Redding SW, Farinacci GC, Smith JA, et al. A comparison between fl uconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection. Spec Care Dentist. 1992;12(1):24-27.
23. Hughes WT, Bartley DL, Patterson GG, et al. Ketoconazole and candidiasis: a controlled study. J Infect Dis. 1983;147(6):1060-1063.
24. Shechtman LB, Funaro L, Robin T, et al. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med. 1984;76(1):91-94.
25. Kirkpatrick CH, Alling DW. Treatment of chronic oral can-didiasis with clotrimazole troches. A controlled clinical trial. N Engl J Med. 1978;299(22):1201-1203.
26. Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fl uconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24(6):1204-1207.
27. Van Roey J, Haxaire M, Kamya M, et al. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defi c Syndr. 2004;35(2):144-150.
28. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus flu-conazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42(8): 1179-1186.
29. Elad S, Wexler A, Garfunkel AA, et al. Oral candidiasis prevention in transplantation patients: a comparative study. Clin Transplant. 2006;20(3):318-324.
30. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fl uconazole-refractory oropharyngeal candidiasis with itra-conazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses. 1999;15(16):1413-1417.
31. Epstein JB, Truelove EL, Hanson-Huggins K, et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer. 2004;12(7):517-525.
32. Glick M, Siegel MA. Viral and fungal infections of the oral cavity in immunocompetent patients. Infect Dis Clin North Am. 1999;13(4):817-831, vi.
33. De Wit S, O'Doherty E, Edwards J, et al. Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodefi ciency virus-positive patients: a phase I study. Antimicrob Agents Chemother. 1998;42(4):903-906.
34. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.
35. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008;14(5):487-494.
36. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets. 2006;7(4):495-504.
37. Odds FC, Hanson MF, Davidson AD, et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol. 2007;56(Pt 8):1066-1075.
38. Bensadoun RJ, Daoud J, El Gueddari B, et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer. 2008;112(1):204-211.
39. Farup PG. Compliance with antiulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther. 1992;6(2):179-186.
40. Carter S, Taylor D, Levenson R. A Question of Choice: Compliance in Taking Medicine. 3rd ed. Medicines Partnership; 2005. http://www.npci.org.uk/ adherence-to- medicines/atm/assess/library/library-other-publication1. php. Accessed March 5, 2010.